Tetraphase Pharmaceuticals Inc Watch

from SC TO-C 140 pages Agreement and Plan of Merger Among: La Jolla Pharmaceutical Company, a California Corporation; Ttp Merger Sub, Inc., a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of June 24, 2020

from 8-K 140 pages Agreement and Plan of Merger Among: La Jolla Pharmaceutical Company, a California Corporation; Ttp Merger Sub, Inc., a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of June 24, 2020

from SC 13D 2 pages May 11, 2020 • the La Jolla Board of Directors Has Approved the Transaction and Authorized Our Execution of the Merger Agreement, Subject to Your Termination of the Acelrx Merger Agreement. • Our Proposal Is Not Subject to Any Financing Contingencies. We Stand Ready to Fund 100% of the Purchase Price With Cash on Hand (As of March 31, 2020, La Jolla Had $77.2 Million of Cash and No Debt). • We Have Reduced the $5 Million Company Net Cash Condition and Target Net Cash Level in the Acelrx Merger Agreement to $4.19 Million to Offset the Termination Fee Payable by Tetraphase to Acelrx. • Our Offer Is Structured as a Tender Offer Rather Than a Merger, Which Means That No Stockholder Vote Is Needed Nor Is a Registration Statement on Form S-4 Required. as a Result, Our Transaction Can Be Completed on an Accelerated Timeline

from 8-K 86 pages Agreement and Plan of Merger Among: Melinta Therapeutics, Inc., a Delaware Corporation; Toronto Transaction Corp., a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of June 4, 2020

from 425 26 pages Amendment No. 2 to Agreement and Plan of Merger

from 8-K 25 pages Amendment No. 2 to Agreement and Plan of Merger

from 425 25 pages Amendment No. 2 to Agreement and Plan of Merger

from 8-K 28 pages Amendment to Agreement and Plan of Merger

from 425 28 pages Amendment to Agreement and Plan of Merger

from 425 27 pages Amendment to Agreement and Plan of Merger

from 8-K 132 pages Agreement and Plan of Merger Among: Acelrx Pharmaceuticals, Inc., a Delaware Corporation; Consolidation Merger Sub, Inc. a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of March 15, 2020

from 425 134 pages Agreement and Plan of Merger Among: Acelrx Pharmaceuticals, Inc., a Delaware Corporation; Consolidation Merger Sub, Inc. a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of March 15, 2020

from DEFA14A 132 pages Agreement and Plan of Merger Among: Acelrx Pharmaceuticals, Inc., a Delaware Corporation; Consolidation Merger Sub, Inc. a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of March 15, 2020